Latest news for Allergy Therapuetics (OTC:AGYTF) Stock

Allergy Therapeutics PLC is active in the healthcare sector in the United Kingdom. It is a pharmaceutical company mainly engaged in the treatment and prevention of allergies with aluminum-free products. The company's geographical segment includes Central Europe; Southern Europe and the Rest of the World. It generates maximum revenue from Central Europe which includes Germany, Austria, Netherlands, and Switzerland.

Earnings

News

AGYTF

Allergy Therapeutics Pre-Tax Profit Drops

Allergy Therapeutics Posts Surge In H1 Profit

ALLERGY THERAPEUTICS PLC by Allergy Therapeutics Plc.

Allergy Therapeutics PLC

Allergy Therapeutics PLC (OTC: <a class="ticker" href="/stock/agytf#OTC">AGYTF</a>) reported a decline in its profit for the full year.
Allergy Therapeutics' pretax profit for the year slipped to 654,000 pounds ($1.0 million), versus GBP1.1 million in the year-ago period. 
Its revenue increased to GBP43.2 million from GBP42.0 million.
CEO Manuel Llobet said, "Growth in the European markets is expected to be relatively slow in the coming year but with the continued momentum across the company's activities, the outlook is very positive and we expect to increase our market share into the next year, delivering improved top-line growth."

Allergy Therapeutics PLC (OTC: AGYTF) reported a surge in its first half profit. 

Allergy Therapeutics' pretax profit for the period rose to GBP8.2 million, from GBP6 million in 2010. However, profit after interest and tax climbed to GBP8.6 million from GBP5.9 million. Its revenue gained 4% to GBP28.5 million from GBP27.4 million. 

Allergy Therapeutics' operating profit climbed to GBP8.0 million versus GBP7.3 million.

Allergy Therapeutics (GB:AGY) has released an update. Allergy Therapeutics has secured an additional £5 million from its amended loan facility with...

Allergy Therapeutics Bolsters Financial Position

Allergy Therapeutics (GB:AGY) has released an update. Allergy Therapeutics has reported successful dose escalation in its Phase I/IIa VLP Peanut PR...

Allergy Therapeutics Advances in Peanut Allergy Trial

Allergy Therapeutics (GB:AGY) has released an update. Allergy Therapeutics has secured a £40 million loan facility from Hayfin Capital Management a...

Allergy Therapeutics Strengthens Financial Position with New Funding

Allergy Therapeutics (GB:AGY) has released an update. Allergy Therapeutics has begun a groundbreaking Phase III trial for its Grass MATA MPL immuno...

Allergy Therapeutics Launches Pediatric Trial for Allergy Vaccine

Allergy Therapeutics (GB:AGY) has released an update. Allergy Therapeutics is showing signs of financial recovery with a notable revenue increase i...

Allergy Therapeutics Sees Growth and Strategic Advances

Allergy Therapeutics (GB:AGY) has released an update. Allergy Therapeutics has shown promising financial recovery with its first half-year revenue ...

Allergy Therapeutics Shows Financial Turnaround and Clinical Progress

Allergy Therapeutics (GB:AGY) has released an update. Allergy Therapeutics PLC has released its Annual Report for the financial year ending June 20...

Allergy Therapeutics Unveils Incentive Plans and Share Repurchase

Allergy Therapeutics (GB:AGY) has released an update. Allergy Therapeutics has commenced a pioneering Phase III trial to assess the long-term effec...

Allergy Therapeutics Begins Innovative Paediatric Allergy Trial

Allergy Therapeutics (GB:AGY) has released an update. Allergy Therapeutics has announced promising interim results from its Phase I/IIa trial of VL...

Allergy Therapeutics Shows Promising Results for Peanut Allergy

The latest announcement is out from Allergy Therapeutics ( ($GB:AGY) ). Allergy Therapeutics has announced a rectification of an administrative ove...

Allergy Therapeutics Rectifies Share Option Oversight

Allergy Therapuetics

Allergy Therapeutics PLC (OTC: <a class="ticker" href="/stock/agytf#OTC">AGYTF</a>) reported a decline in its profit for the full year.

Allergy Therapeutics' pretax profit for the year slipped to 654,000 pounds ($1.0 million), versus GBP1.1 million in the year-ago period. 

Its revenue increased to GBP43.2 million from GBP42.0 million.

CEO Manuel Llobet said, "Growth in the European markets is expected to be relatively slow in the coming year but with the continued momentum across the company's activities, the outlook is very positive and we expect to increase our market share into the next year, delivering improved top-line growth."

Allergy Therapeutics PLC (OTC: AGYTF) reported a surge in its first half profit. 

Allergy Therapeutics' pretax profit for the period rose to GBP8.2 million, from GBP6 million in 2010. However, profit after interest and tax climbed to GBP8.6 million from GBP5.9 million. Its revenue gained 4% to GBP28.5 million from GBP27.4 million. 

Allergy Therapeutics' operating profit climbed to GBP8.0 million versus GBP7.3 million.


Comments

Allergy Therapuetics

News

Latest news for Allergy Therapuetics (OTC:AGYTF) Stock

Monday, September 21, 2015

Friday, March 30, 2012

Popular Channels

Tools & Features

Partners & Contributors

About Benzinga